Semorex' "super" molecularly- imprinted polymers

17 April 2001

Israeli biotechnology company Semorex has unveiled a new class of"super" molecularly-imprinted polymers, which it says work at lower concentrations than their natural counterparts, with the potential for greater stability, lower costs and customized manufacture.

"Super" MIPs' superior affinity and synthetic origins will allow the development of "smart drugs," improved diagnostic and research tools that can be programmed to selectively bind to target molecules, proteins and other substances, says the firm. Their enhanced binding abilities can be extended to other compounds, it adds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight